Physician profile
Michael Bazel
NPI 1598712978
$3,283.63
in general payments reported to CMS, 2019-2025
21 companies · $373 in 2025
The $373 reported for 2025 was more than what 91% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $618 · 2021: $713 · 2022: $498 · 2023: $507 · 2024: $468 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $689.40 | 2019-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $669.68 | 2020-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $587.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $258.67 | 2020-2023 | Verquvo |
| Abbvie INC. | $194.45 | 2020-2023 | Viberzi, Linzess |
| Electronic Waveform Lab, INC. | $185.99 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $88.47 | 2023 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $77.23 | 2019-2021 | |
| Eisai INC. | $68.68 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.00 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $65.75 | 2022 | |
| Abbott Laboratories | $63.10 | 2025 | Id Now Instrument |
| Hikma Pharmaceuticals USA | $48.36 | 2021-2022 | |
| Pfizer INC. | $46.43 | 2020-2021 | |
| Shield Therapeutics INC | $36.87 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $30.23 | 2021 | |
| Lilly USA, LLC | $27.48 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.68 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.84 | 2023 | |
| Aimmune Therapeutics, INC. | $17.24 | 2025 | Zenpep |
| Philips North America LLC | $15.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.